VC2 HSV Vaccine Description
VC2 vaccine candidate is a live-attenuated, engineered version of HSV-1.
The VC2 vaccine targets facial, ocular, and genital herpes caused by HSV-1 but may also protect against genital herpes caused by HSV-2.
"VC2 is unique in that it is engineered in a way that prevents the virus from entering the neurons, said Dr. Gus Kousoulas, who recently joined Rational Vaccines as Vice President of Scientific Affairs. HSV typically infiltrates a person's neurons and remains latent within the nervous system, and can reactivate to cause substantial disease. Some patients can even be asymptomatic carriers, spreading the virus through skin contact while showing no signs of infection themselves."
VC2 HSV Vaccine Indication
VC2 has demonstrated promise in the treatment of Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) as well as facial and ocular herpes in several animal model studies.
VC2 HSV Vaccine News
April 5, 2021 - Rational Vaccines announces a licensing agreement with Louisiana State University for a vaccine technology VC2, which demonstrates great promise in treating HSV1 and HSV2. "We are so very excited about adding this incredible science to the Rational Vaccines arsenal and partnering with Louisiana State University in the fight against HSV," said Rational CEO Agustin Fernandez.
March 7, 2018 - Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. 'Kousoulas said his team's research has been able to demonstrate that the live-attenuated HSV-1 VC2 vaccine strain is unable to establish latency in vaccinated animals and produces a robust immune response capable of completely protecting mice against lethal ocular and vaginal HSV-1 or HSV-2 infections. He said the guinea pig represents the best small animal model of genital HSV-2 disease.'